Azacitidine + Rezatapopt
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndrome
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Trial Timeline
Jan 30, 2025 → Aug 27, 2029
NCT ID
NCT06616636About Azacitidine + Rezatapopt
Azacitidine + Rezatapopt is a phase 1 stage product being developed by PMV Pharmaceuticals for Myelodysplastic Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06616636. Target conditions include Myelodysplastic Syndrome, Acute Myeloid Leukemia.
What happened to similar drugs?
7 of 19 similar drugs in Myelodysplastic Syndrome were approved
Approved (7) Terminated (7) Active (7)
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06616636 | Phase 1 | Recruiting |
Competing Products
20 competing products in Myelodysplastic Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| JSP191 | Jasper Therapeutics | Phase 1 | 11 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 14 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 35 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 35 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 35 |
| decitabine + decitabine | Eisai | Phase 2 | 35 |
| decitabine + azacitidine | Eisai | Approved | 35 |
| Decitabine | Eisai | Phase 2 | 27 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 29 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 35 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 21 |
| Decitabine | Eisai | Phase 2 | 35 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 32 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 24 |
| Decitabine | Johnson & Johnson | Phase 2 | 35 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 27 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 35 |